Healthcare has entered the "Age of AI," and no major drug company wants to be left behind.
But betting on a hit-or-miss biotech company may not be the best way to capitalize. Instead, at this early stage of the opportunity, select big-cap drug companies may offer better risk-reward profiles.
Tidak ada komentar:
Posting Komentar